CAMP抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P09438(CAMP Antibody) at dilution 1/110. (Original magnification: ×200)    

  
  

CAMP antibodies are autoantibodies targeting the CAMP (cathelicidin antimicrobial peptide) factor, a crucial component of the innate immune system. CAMP, also known as LL-37 in humans, is a cationic antimicrobial peptide produced by epithelial cells and neutrophils. It plays dual roles: defending against bacterial, viral, and fungal pathogens by disrupting microbial membranes, and modulating immune responses by chemoattracting immune cells and influencing cytokine production.

In autoimmune contexts, CAMP antibodies are notably associated with psoriasis and psoriatic arthritis. Research suggests these antibodies may arise from molecular mimicry, where immune responses to microbial CAMP-like proteins (e.g., from *Streptococcus*) cross-react with human CAMP. Elevated anti-CAMP antibody levels correlate with disease severity, implicating them in pathogenesis by potentially neutralizing LL-37's protective functions or forming immune complexes that trigger inflammation.

Additionally, CAMP antibodies are explored as diagnostic biomarkers. Their presence in serum or synovial fluid may aid in differentiating psoriatic arthritis from other rheumatic conditions. Despite progress, their exact pathogenic mechanisms and clinical utility require further validation. Understanding CAMP antibodies bridges microbial immunity, autoimmunity, and chronic inflammation, offering insights into targeted therapies for immune-mediated diseases.